Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

A label-free biosensor based on graphene and reduced graphene oxide dual-layer for electrochemical determination of beta-amyloid biomarkers

  • Sethi, Jagriti
  • Van Bulck, Michiel
  • Suhail, Ahmed
  • Safarzadeh, Mina
  • Perez-Castillo, Ana
  • Pan, Genhua
A label-free biosensor is developed for the determination of plasma-based Aβ1–42 biomarker in Alzheimer’s disease (AD). The platform is based on highly conductive dual-layer of graphene and electrochemically reduced graphene oxide (rGO). The modification of dual-layer with 1-pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) is achieved to facilitate immobilization of H31L21 antibody. The effect of these modifications were studied with morphological, spectral and electrochemical techniques. The response of the biosensor was evaluated using differential pulse voltammetry (DPV). The data was acquired at a working potential of ~ 180 mV and a scan rate of 50 mV s−1. A low limit of detection (LOD) of 2.398 pM is achieved over a wide linear range from 11 pM to 55 nM. The biosensor exhibits excellent specificity over Aβ1–40 and ApoE ε4 interfering species. Thus, it provides a viable tool for electrochemical determination of Aβ1–42. Spiked human and mice plasmas were used for the successful validation of the sensing platform in bio-fluidic samples. The results obtained from mice plasma analysis concurred with the immunohistochemistry (IHC) and magnetic resonance imaging (MRI) data obtained from brain analysis. [Figure not available: see fulltext.], This work was financially supported by H2020 MSCA-ITN-ETN BBDiag project under grant no. 721281. Scanning electron microscopy was performed by the Plymouth Electron Microscopy Centre (PEMC). X-ray photoelectron microscopy was performed by Harwellxps.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel approaches for the treatment of Alzheimer’s and Parkinson’s disease

  • Van Bulck, Michiel
  • Sierra-Magro, Ana
  • Alarcón-Gil, Jesús
  • Pérez Castillo, Ana
  • Morales-García, José A.
Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer's and Parkinson's diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases. This article reviews the current knowledge about these diseases by summarizing the most common features of major neurodegenerative disorders, their causes and consequences, and the proposed novel therapeutic approaches., This work was supported by MINECO (Grants SAF2014-52940-R and SAF2017-85199-P to A.P.-C.) and by Comunidad de Madrid project (B2017/BMD3700). Hereby, we also acknowledge that the financial support from EU H2020 MSCA-ITN-ETN BBDiag project under grant No. 721281.CIBERNED is funded by the Instituto de Salud Carlos III. J.A.M.-G. is a post-doctoral fellow from CIBERNED. M.V.B. is a pre-doctoral MSCA-ITN-ETN fellow and member of CIBERNED., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A label-free biosensor based on graphene and reduced graphene oxide dual-layer for electrochemical determination of beta-amyloid biomarkers

  • Sethi, Jagriti
  • Van Bulck, Michiel
  • Suhail, Ahmed
  • Safarzadeh, Mina
  • Pérez Castillo, Ana
  • Pan, Genhua
A label-free biosensor is developed for the determination of plasma-based Aβ1–42 biomarker in Alzheimer’s disease (AD). The platform is based on highly conductive dual-layer of graphene and electrochemically reduced graphene oxide (rGO). The modification of dual-layer with 1-pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) is achieved to facilitate immobilization of H31L21 antibody. The effect of these modifications were studied with morphological, spectral and electrochemical techniques. The response of the biosensor was evaluated using differential pulse voltammetry (DPV). The data was acquired at a working potential of ~ 180 mV and a scan rate of 50 mV s−1. A low limit of detection (LOD) of 2.398 pM is achieved over a wide linear range from 11 pM to 55 nM. The biosensor exhibits excellent specificity over Aβ1–40 and ApoE ε4 interfering species. Thus, it provides a viable tool for electrochemical determination of Aβ1–42. Spiked human and mice plasmas were used for the successful validation of the sensing platform in bio-fluidic samples. The results obtained from mice plasma analysis concurred with the immunohistochemistry (IHC) and magnetic resonance imaging (MRI) data obtained from brain analysis., This work was financially supported by H2020 MSCA-ITN-ETN BBDiag project under grant no. 721281., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Aβ-Induced alterations in membrane lipids occur before synaptic loss appears

  • Van Bulck, Michiel
  • Brandt, Nicola
  • Claus, Ralf A.
  • Gräler, Markus
  • Bräuer, Anja U.
Loss of active synapses and alterations in membrane lipids are crucial events in physiological aging as well as in neurodegenerative disorders. Both are related to the abnormal aggregation of amyloid-beta (Aβ) species, generally known as amyloidosis. There are two major known human Aβ species: Aβ(1–40) and Aβ(1–42). However, which of these species have more influence on active synapses and membrane lipids is still poorly understood. Additionally, the time-dependent effect of Aβ species on alterations in membrane lipids of hippocampal neurones and glial cells remains unknown. Therefore, our study contributes to a better understanding of the role of Aβ species in the loss of active synapses and the dysregulation of membrane lipids in vitro. We showed that Aβ(1–40) or Aβ(1–42) treatment influences membrane lipids before synaptic loss appears and that the loss of active synapses is not dependent on the Aβ species. Our lipidomic data analysis showed early changes in specific lipid classes such as sphingolipid and glycerophospholipid neurones. Our results underscore the potential role of lipids as a possible early diagnostic biomarker in amyloidosis-related disorders., This research was funded by H2020 MSCA-ITN-ETN BBDiag project under grant No. 721281.